Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

PURPOSE: Genetically-targeted therapies are both promising and costly advances in the field of oncology. Several treatments for metastatic melanoma with a mutation in the BRAF gene have been approved. They extend life but are more expensive than the previous standard of care (dacarbazine). Vemurafen...

Descripción completa

Detalles Bibliográficos
Autores principales: Curl, Patti, Vujic, Igor, van ‘t Veer, Laura J., Ortiz-Urda, Susana, Kahn, James G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157865/
https://www.ncbi.nlm.nih.gov/pubmed/25198196
http://dx.doi.org/10.1371/journal.pone.0107255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157865/
https://www.ncbi.nlm.nih.gov/pubmed/25198196
http://dx.doi.org/10.1371/journal.pone.0107255

Ejemplares similares